ArticleFrontiers in aging neuroscience2025
Cerebral perfusion and gray matter volume alterations associated with cognitive impairment in metabolic syndrome with cerebral small vessel disease.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cognitive fatigue is related to reduced cerebral perfusion and sustained attention in patients with post COVID-19 condition: An fMRI study.Neuroimage. Reports · 2026Article
- Cardiovascular-kidney-metabolic syndrome stages 0-3 and cognitive decline in Chinese adults: a longitudinal analysis from the China health and retirement longitudinal study.BMC cardiovascular disorders · 2026Article
- One-month early time-restricted eating enhances cognition via white matter-cortical pathways in males with metabolic syndrome: evidence from TBSS and SBM analyses.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Metabolic syndrome (MetS) combined with cerebral small vessel disease (CSVD) is associated with cognitive dysfunction. However, the underlying mechanisms remain poorly understood. This study investigated the roles of brain perfusion and gray matter volume (GMV) in cognitive dysfunction in patients with MetS combined with CSVD (MetS-CSVD). Methods: This study enrolled 180 MetS patients and 86 healthy controls (HCs). Patients with MetS were categorized into MetS without CSVD (MetS-NCSVD) ( Results: Compared to the MetS-NCSVD and HC groups, the MetS-CSVD group displayed significantly reduced perfusion and GMV in the frontal and temporal lobes. Partial correlation analysis revealed that CBF and GMV in the frontotemporal lobe were strongly associated with overall cognitive function, executive function, and language function in the MetS-CSVD group. MLRA identified the CSVD score as the sole independent factor negatively associated with cognitive performance. Mediation analysis revealed that CBF and GMV in the frontal lobes mediated the relationship between the CSVD score and overall cognitive and executive function. Conclusion: CBF and GMV were strongly associated with cognitive performance. CSVD, rather than individual components of MetS, mediated cognitive impairment in patients with MetS-CSVD. CSVD likely contributes indirectly to cognitive impairment through its effects on CBF and GMV in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.